A $30 million merger among Community Direct DX (CDx), Scienetix, and the R&D division of Advanta Genetics has formed McKinney-based OSPRI, a next-generation biotechnology company and “one of the world’s first fully vertically integrated” molecular testing platforms.

OSPRI specializes in polymerase chain reaction (PCR)-based infectious disease detection, and it develops and delivers advanced tools that improve access to high-quality care across key healthcare segments—including women’s health, primary care, urgent care, urology, hospitals, and clinical reference laboratories.

“PCR testing is foundational for infectious disease detection, but cost and complexity have kept it out of reach for many,” Co-founder Steve Sorey, partner at OSPRI, said in a statement. “To unlock widespread adoption, we must reduce both. At OSPRI, we’re obsessed with doing more with less—making PCR faster, cheaper, and better for everyone involved.”

In addition to assay development, OSPRI said it delivers an end-to-end solution—covering manufacturing, lab buildout, revenue cycle management, and regulatory support—empowering providers to operate high-complexity labs in-house with greater speed, accuracy, and financial control.

Funding and leadership

OSPRI said it’s backed by up to $30 million of strategic funding from Catalio Capital Management, a healthcare investment firm with deep expertise in diagnostics. This partnership will support OSPRI’s continued growth, platform development, and national expansion.

“OSPRI delivers a powerful solution for physician groups and laboratories—simplifying infectious disease testing while creating strong clinical and commercial value,” Catalio Partner Jonathan Blankfein said in a statement. “We’re proud to support their mission to expand access to rapid, provider-centric diagnostics.”

OSPRI’s scientific leadership includes Chief Science Officer Dr. Rahul Sharma, Chief Innovation Officer Dr. Sadia Almas, and Chief Clinical Officer Dr. Alaina Vincent.

Redefining PCR testing

The company said its technology is redefining PCR testing through:

• 20–50% reduction in overall testing costs
• 50–70% decrease in testing time and workflow steps
• Up to 4x increase in testing capacity
• Customized assays tailored to provider specialty and patient population
• Reduced lab errors through simplified workflows
• A comprehensive menu of 80+ PCR tests covering 250+ pathogens and AMR genes

Enabling ‘better, faster care’

Founded in 2015, Community Direct DX has launched more than 60 labs nationwide. Scienetix brings deep expertise in molecular bioengineering, while Advanta R&D has led advancements in high-resolution genomics and contributed to national public health initiatives.

“Our production capabilities have grown exponentially,” OSPRI Co-Founding Partner Jeremy Adamic said in a statement. “From a limited menu and basic QC, we now deliver over 40,000 tests per day with multilayered quality control—scaling both volume and reliability.”

OSPRI said that over the next 12–24 months, it plans to expand its R&D team by 40% and grow commercial operations by 25% to meet increasing demand. The company currently serves clients across 20 states and multiple clinical specialties.

“OSPRI exists to solve the real problems of cost and complexity in infectious disease testing,” said Vincent, the company’s chief clinical officer. “Innovation should be accessible—not exclusive. Our goal is to enable better, faster care for more patients by equipping providers with the tools they need to lead.”

Don’t miss what’s next. Subscribe to Dallas Innovates.

Track Dallas-Fort Worth’s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.